7 1 5 l e t t e r s ( Supplementary Fig. 1 ) to find a combination of small molecules that accelerates acquisition of postmitotic neuron markers from hPSCs. Cells were monitored for loss of the human neuroectoderm marker PAX6 (ref. 10) and induction of neuronal β3-tubulin (TUBB3 + TUJ1 + ) 11 at day 10 after addition of LSB. We discovered that a combination of three small molecules (SU5402, CHIR99021 and DAPT, called 3i for 'three inhibitors') added on day 2 ( Supplementary Fig. 2 ) abolishes PAX6 expression and induces TUBB3 in hPSCs at day 10 of differentiation ( Fig. 1b) . SU5402 is a potent inhibitor of vascular epithelial growth factor (VEGF), fibroblast growth factor (FGF) and platelet-derived growth factor (PDGF) tyrosine kinase signaling 12 . CHIR99021 can act as a WNT agonist by selectively inhibiting glycogen synthase kinase-3β (GSK-3β) and thereby stabilizing β-catenin 13 . DAPT is a γ-secretase inhibitor that blocks Notch signaling 14 .
Considerable progress has been made in identifying signaling pathways that direct the differentiation of human pluripotent stem cells (hPSCs) into specialized cell types, including neurons. However, differentiation of hPSCs with extrinsic factors is a slow, step-wise process, mimicking the protracted timing of human development. Using a small-molecule screen, we identified a combination of five small-molecule pathway inhibitors that yield hPSC-derived neurons at >75% efficiency within 10 d of differentiation. The resulting neurons express canonical markers and functional properties of human nociceptors, including tetrodotoxin (TTX)-resistant, SCN10Adependent sodium currents and response to nociceptive stimuli such as ATP and capsaicin. Neuronal fate acquisition occurs about threefold faster than during in vivo development 1 , suggesting that use of small-molecule pathway inhibitors could become a general strategy for accelerating developmental timing in vitro. The quick and high-efficiency derivation of nociceptors offers unprecedented access to this medically relevant cell type for studies of human pain.
The in vitro derivation of postmitotic neurons from hPSCs requires extended culture periods typically lasting 30 d or more 2, 3 . Protracted in vitro differentiation of hPSCs is thought to reflect the chronology of human development in vivo 4 . Identifying in vitro strategies to overcome this slow pace is a major challenge for realizing the full potential of hPSCs in basic biology and human disease modeling 5 .
Here we describe a combinatorial small molecule-based approach to rapidly coax pluripotent cells into nociceptors. Previously, we reported that dual-SMAD inhibition efficiently neuralizes hPSCs 6 . Follow-up studies have described the use of small molecules that replace Noggin 7, 8 , and, similarly, we identified a bone morphogenetic protein (BMP) inhibitor LDN-193189 (ref. 9 ) that can replace Noggin for neuralization of hPSCs ( Fig. 1a , abbreviated LSB for the two inhibitors LDN-193189 and SB431542). Using LSB, we screened candidate compounds that modulate key developmental pathways npg l e t t e r s forkhead box G1 (FOXG1) 6 . Unexpectedly, we observed homogenous expression of ISL1 and BRN3A ( Fig. 1h,i) , canonical markers of sensory neurons 17, 18 , indicating that the resulting neurons have peripheral nervous system (PNS) rather than CNS identity at day 12. The emergence of BRN3A and ISL1 expression under these conditions was also observed for human induced pluripotent stem cells, such as line C14 (Fig. 1j,k) . There are three main subsets of sensory neurons-proprioceptors, mechanoreceptor neurons and nociceptors-distinguished by the specific expression pattern of neurotrophic receptors 19 . More than 60% of all cells expressed neurotrophic tyrosine kinase receptor-1 (NTRK1) measured by FACS at day 10 ( Fig. 1l ; in contrast, NTRK2 and NTRK3 could not be detected by immunofluorescence or FACS ( Supplementary Fig. 4) , indicating that the majority of LSB3i-induced neurons were nociceptors.
We quantitatively assessed the reproducibility of LSB3i treatment across hPSC lines. Two hiPSC lines (C14 and C72), which have been shown to efficiently neuralize 20 , homogeneously gave rise to Nestin + cells when treated with LSB (>95%), and formed TUJ1 + cells when treated with LSB3i (40% for C14 and 33% for C72; Fig. 1m ). We obtained a further increase in neuronal yield upon passaging of bulk cultures ( Supplementary Fig. 5 ), suggesting that the lower efficiency in those two hiPSC lines at day 10 is probably due to a slight delay in differentiation. Sorting based on NTRK1 expression can be used to further enrich for BRN3A + , ISL1 + and TUJ1 + neurons ( Supplementary Fig. 6 ).
Nociceptors arise via two possible lineages during human development: SOX10 + neural crest 21, 22 can generate trunk nociceptors that flank the spinal cord 23 ; alternatively, head placode contributes to the trigeminal nociceptors responsible for innervation of the face 24, 25 . To distinguish between these possibilities, we generated a transgenic SOX10øGFP bacterial artificial chromosome hPSC line that enriches for neural crest markers in the GFP fraction ( Supplementary Fig. 7 ). We used FACS to monitor GFP expression at 4 d, npg l e t t e r s with LSB, LSB and CHIR99021 (LSB/CHIR), or LSB3i ( Fig. 2a-c) .
A majority of the cells in culture became SOX10øGFP + by day 12 of differentiation when CHIR99021 was present (70% for LSB/C and 80% for LSB3i; Fig. 2d ). This result indicates that the LSB3i cells adopt a neural crest identity, supporting our earlier observation that CHIR99021-mediated neural crest induction is required for the generation of LSB3i nociceptors. Treatment with SU5402 accelerated neural crest cell fate choice, as LSB3i-or LSB/SU/CHIR-treated cells acquired neural crest identity more rapidly than did LSB/CHIR and LSB/CHIR DAPT-treated hPSCs ( Fig. 2d and Supplementary Fig. 8 ).
To determine whether SOX10øGFP + cells can give rise to nociceptors, we sorted GFP + cells at day 8 of LSB3i treatment (60% of total) and maintained them in 3i until day 11, resulting again in ISL1 + BRN3A + TUJ + neurons ( Fig. 2e,f) . These data show that LSB3i differentiates hPSCs toward nociceptors via a SOX10 + neural crest intermediate. Immunocytochemical studies confirmed that SOX10 was never coexpressed in neuronal β3-tubulin (TUJ1) cells. Persisting SOX10 + precursor cells ( Fig. 2d ) could be largely eliminated (<5%) upon passage and replating of LSB3i cells (Supplementary Fig. 9 ). Cells retaining SOX10øGFP expression, when FACS sorted by day 14, gave rise to mixed neural crest progeny ( Supplementary Fig. 10 ). LSB3i nociceptors expressed high levels of glutamate ( Fig. 2g) , consistent with an excitatory glutamatergic neuron. During development, when BRN3A is established, nociceptors uniquely express NTRK1 and RUNX1 and will differentiate into peptidergic and nonpeptidergic subtypes that are distinguished by whether RUNX1 expression persists 19, 26 . From day 8 to day 14, we observed expression of RUNX1 followed by activation of RET expression, coinciding with neuronal process formation ( Fig. 2h) . However, in most of the cells RUNX1 expression was extinguished by day 14 (Fig. 2h) .
We examined differentiation and maturation behavior to further confirm that LSB3i-derived neurons were nociceptors. LSB3i nociceptors will grow long term in N2 medium with human β-nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF) and glial cell-derived neurotrophic factor (GDNF). By day 15, peripherin was ubiquitously expressed in cells doubly labeled with BRN3A and ISL1 (PRPH, Fig. 2i ). LSB3i neurons could be cultured long term, and were often organized into ganglia-like clusters by day 30 LSB3i (Fig. 2j) . Expression of Substance P and calcitonin gene-related peptide (CGRP) was observed in >60% of LSB3i-induced neurons following sorting for NTRK1, indicating the presence of a subset of peptidergic nociceptors (Fig. 2k,l ; day 30 of differentiation) 26 .
We analyzed global gene expression (days 2, 3, 5, 7, 9 and 15) in both LSB-and LSB3i-treated hPSCs to characterize the timing of events during the differentiation. Selected markers for neuroectoderm, neural crest, neurons and nociceptors ( Supplementary Table 1 ) showed distinct phases of differentiation ( Fig. 3a) . Array-based transcriptome analysis also confirmed many of our immunofluorescence findings (Fig. 3b,c) . For instance, ISL1, POU4F1 (BRN3A), SOX10, TAC1 (pro-peptide to Substance P), NTRK1, PRPH and VGLUT2 were all upregulated. Conversely, we observed downregulation of DLK1, LHX2, OTX2, LEFTY2, PAX6 and HES5 (Fig. 3b) , all genes shown by our laboratory to mark human embryonic stem cell (hESC)-derived primitive neuroectoderm 6, 27 .
In addition, microarray analysis provided further evidence for nociceptor intermediate cell fates, distinct from mechanoreceptor neurons and proprioceptors (Supplementary Fig. 11 ). During mouse development, the neurogenin basic helix-loop-helix proteins mediate two sequential waves of neurogenesis to form the dorsal root ganglia (DRG) 28, 29 . The first wave, marked by Neurog2 expression, gives rise to mechanoreceptor neurons and proprioceptors, and the second, marked by Neurog1 expression, gives rise to nociceptors. When hPSCs were treated with LSB, NEUROG2 expression was strongly induced by day 7 (Fig. 3c) . In contrast, hPSCs treated with LSB3i showed a less pronounced induction of NEUROG2 by day 7 but selective induction of NEUROG1 by day 9 (Fig. 3c) . We further observed that selective nociceptor generation with LSB3i depends on continuous CHIR treatment (days 2-14). Shorter CHIR pulses (days 2-4 or days 2-8) induced similar levels of SOX10 but high expression of ASCL1, NTRK1 and NTRK2, markers of autonomic neurons, mechanoreceptor neurons and proprioceptors, respectively (Supplementary Fig. 12 ).
Functional evidence, the 'gold standard' for demonstrating nociceptor identity, depends on ion channels and receptors that detect noxious stimuli 26 . We first assessed the expression of a broad range of mature nociceptive markers during LSB3i (Fig. 4a) . The sodium channels SCN9A, SCN10A and SCN11A, the purinergic receptor P2RX3 2  3  5  7  9  1 5  2  3  5  7  9  1 5  2  3  5  7  9  1 5  2  3  5  7  9  1 5  2  3  5  7  9  1 5  2  3  5  7  9  1 5   2  3  5  7  9  1 5  2  3  5  7  9  1 5  2  3  5  7  9  1 5  2  3  5  7  9  1 5  2  3  5  7  9  1 npg l e t t e r s and the vanilloid receptors TRPV1 and TRPM8 were upregulated by day 15. SCN10A is selectively expressed in both rodent and human nociceptive sensory neurons 30 and is thought to underlie the upstroke of the action potential and repetitive firing in C-fibers 31 . Using a current-voltage protocol, we observed voltage-gated currents in all LSB3i-derived cells with a neuronal morphology (I = −23.7 ± 3.5 nA at 0 mV, n = 30). Currents were fully blocked in the majority of cells of cells (24 of 30 recordings) by 500 nM TTX, but 500 µM Cd 2+ in the extracellular solution reduced the current by <5% (n = 5), suggesting that most of the voltage-gated current is carried by Na + rather than Ca 2+ . We observed TTX-resistant (TTX-R) currents (mean current amplitude = −402 ± 112 pA), a characteristic feature of SCN10A + nociceptors, in 6 cells out of 24. Application of the selective SCN10A blocker A-803467 (ref. 32 ) blocked >90% of the TTX-R currents in all cases (Fig. 4b) .
To further test the functional expression of SCN10A, we applied A-803467 and recorded action potential activity in current clamp mode. Action potentials were detected in all cells with a neuronal morphology in response to suprathreshold current injections. In all cells with multiple action potentials, treatment with A-803467 at 500 nM (n = 6 cells) or 250 nM (n = 5 cells) decreased the repetitive firing without affecting the first action potential (Fig. 4c) . Similarly, A-803467 had no effect on the cells with a single action potential (Supplementary Fig. 13, n = 6) . These data suggest that SCN10A is commonly expressed in LSB3i-derived neurons and contributes to the repetitive action potential firing. The expression data and functional characterization of SCN10A strongly indicate that LSB3i yields a population of neurons with a nociceptive sensory phenotype. We also evaluated calcium flux of LSB3i nociceptors in response to 1 µM capsaicin, the noxious component in chili peppers, known to activate a subset of nociceptive sensory neurons through binding to the TRPV1 vanilloid receptor 33 and to 30 µM α,β-methylene-ATP, a selective agonist of P2RX3 (ref. 34); this activation mimics inflammatory pain (Fig. 4d) . α,β-Methylene-ATP induced a robust calcium response. For capsaicin, we observed activation in a subset of neuronal processes and rare cell bodies (1-2% of cells), indicating either significant neurite arborization of a few responding cells, or selective calcium signaling sequestered to the processes (Supplementary Fig. 14) .
To confirm that α,β-methylene-ATP was indeed activating the P2RX3 receptor, we carried out both calcium flux ( Fig. 4e and  Supplementary Fig. 14) and electrophysiological analyses with the selective P2RX3 antagonist A-317491 (ref. 32) (Fig. 4f) . Pretreatment with A-317491 significantly (**P < 0.01; one-way ANOVA, Dunnett's test) and in a dose-dependent manner decreased calcium flux response induced by 30 µM α,β-methylene-ATP (Fig. 4e) . Focal application of 10 µM α,β-methylene-ATP to the LSB3i neurons resulted in typical P2RX3 currents (2.1 ± 0.46 nA, n = 6) with signature fast activation and fast desensitization (n = 6, Fig. 4f ). Exposure to 1 µM A-317491 blocked the current in all cells tested (average reduction of 93 0.1 ± 2.3% (n = 5)).
The speed with which stable, mature and functional neuronal cell fates can differentiate from hPSCs using this combined smallmolecule approach (Supplementary Fig. 15 ) remains the most unexpected finding. The time frame of 15 d for the generation of a functionally mature neuron phenotype is accelerated compared with estimates of nociceptor emergence during human development (30-50 d) 35 . hPSCs under LSB3i seem to transit through all the major intermediate stages expected for generating mature nociceptors, but at a much faster pace. Upregulation of ISL1 and BRN3A are concomitant with expression of SOX10, starting between days 5 and 7. The optimal time to add LSB3i is day 2 of dual-SMAD inhibition, similar to a previous finding from our laboratory showing an early requirement for sonic hedgehog treatment (day 2) for effective induction of FOXA2 and human floor plate differentiation 27 . The potent role of CHIR99021 in the derivation of neural crest-derived sensory neurons is probably related to activation of canonical WNT signaling, which is known to be essential during early neural crest specification 36 and npg l e t t e r s capable of instructing naive neural crest precursors toward the sensory neuron lineage 37 . We report efficient neural crest induction in the presence of the BMP-inhibitory compound LDN-193189 and the FGF-inhibitory molecule SU5402, supporting the notion that activation of WNT by CHIR rather than activation of BMPs or FGFs is crucial for directing neural crest lineage in hPSCs. Previous studies in zebrafish found that Notch signaling during neural crest development suppresses sensory neuron differentiation 38 , consistent with the effects of DAPT observed our study. The functional data in the current study confirm differentiation of hPSCs into nociceptive sensory neurons. LSB3i differentiation and growth conditions drive the cells predominantly into a P2RX3expressing phenotype, with some capsaicin-responsive cells. This is consistent with the expression profiling data (Fig. 4a) , which show stronger upregulation of P2RX3 than of TRPV1 and may indicate the generation of a predominant P2RX3 + , TRPV1 − cell type, similar to the rodent nonpeptidergic IB4 + population. The downregulation of RUNX1 and upregulation of RET observed between days 8 and 14 in culture are consistent with this hypothesis (Fig. 2h) , and may recapitulate the switch from the NTRK1 (TrkA) + peptidergic population to the TrkA-negative, Ret + nonpeptidergic population observed in rodent systems [39] [40] [41] [42] . Loss-of-function studies during mouse development suggest that early Runx1 expression is crucial for inducing ion channel expression and that late expression is a key determinant of the nonpeptidergic switch [43] [44] [45] . We report broad RUNX1 expression at day 8 and robust ion channel expression. However, once ion channel expression is established by day 15, RUNX1 levels decrease in most cells (Fig. 2h) , an observation that diverges with published RUNX1 data in the mouse. Future studies will be required to determine whether this result represents a true difference between human and rodent nociceptor development or an idiosyncrasy of our culture system.
Taken together, our data show that combined small-molecule inhibition of endogenous signals provides a rapid, efficient, nongenetic and cost-effective means to modulate hPSC cell fates. The scalable generation of hPSC-derived nociceptors using LSB3i (summarized in Supplementary Table 2 and Supplementary Fig. 15 ) provides a method for basic biology studies and for drug discovery related to human pain. We envisage that strategies similar to LSB3i can be developed for the rapid induction of other neuron subtypes in the PNS and CNS and may lead to a new generation of directeddifferentiation protocols.
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